Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D. Carvajal, Paul Nathan, Shirley Spratt et al.|Journal of Clinical Oncology|2018Cited by 274
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.Jean‐Charles Soria, Michael Millward, Hui Gan et al.|Journal of Clinical Oncology|2012Cited by 14
A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.Adam Sharp, Hendrik‐Tobias Arkenau, Anja Williams et al.|Journal of Clinical Oncology|2022Cited by 12
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Pavlina Spiliopoulou, Sarah P. Blagden, Farasat Kazmi et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 8
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).Andrew L. Coveler, T.R. Jeffry Evans, Farasat Kazmi et al.|Journal of Clinical Oncology|2021Cited by 6